( effect of erlotinib.In contrast rese...)Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting,Health

effect of erlotinib. In contrast, researchers found that steroids and immunosuppressive agents may potentiate the cytotoxic effect of anti-EGFR inhibitors in the skin, thus providing a possible explanation for the erratic and mixed therapeutic results often observed with the use of these agents. This data was presented by Roman Perez-Soler, M.D., Chief of the Division of Oncology in the Department of Medicine at the Albert Einstein College of Medicine in New York in an abstract titled "Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas Menadione (Vit K3) exerts a protective effect: implications for the management of the skin rash" (#9124).

Results from a Phase I, single-center, open-label, randomized, 2-arm crossover study of Marqibo in Stage III or IV melanoma patients were presented in an abstract titled "A pharmacokinetic comparison of the Marqibo 3- and 5- vial injection kits in metatastic melanoma patients" (#8575) by members of the study team lead by Dr. Agop Bedikian of the UT MD Anderson Cancer Center in Houston. The study showed that the 3- and 5- vial kits produced a bioequivalent pharmacokinetic (PK) profile. Single agent Marqibo was also generally well tolerated in metastatic melanoma patients with an adverse event profile similar to conventional vincristine. In addition, Marqibo showed promising single agent activity against Stage IV metastatic melanoma. Hana is currently developing Marqibo for use in the treatment of patients with acute lymphoblastic leukemia.

About Menadione

Menadione, a small organic molecule, has been shown to activate the Epidermal Growth Factor Receptor (EGFR) signaling pathway by inhibiting phosphatase activity. EGFR inhibitors or EGFRIs are currently used to treat non-small cell lung cancer, pancreatic, colorectal, and head & neck cancer. Approximately seventy-five percent of patients taking EGFRIs develop an associat
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting